The deaf community is being left behind in crucial conversations about gene-editing technologies, according to the British Deaf Association (BDA). A recent letter to UKPulse Media from Tom Lichy, Head of Policy and Research at the BDA, highlights the urgent need for inclusive dialogue as scientific breakthroughs in gene therapy accelerate.
A recent poll by the Progress Educational Trust revealed a clear distinction in public opinion on gene editing. While there is majority support among the UK public for using this technology to correct life-threatening genetic conditions, this consensus does not extend to non-life-threatening conditions such as deafness. The BDA argues that discussions surrounding gene editing often fail to be made accessible in signed languages, effectively marginalising deaf signers from contributing to decisions that profoundly affect their lives.
The issue gained further prominence in April when the US Food and Drug Administration (FDA) approved a specific gene therapy for deafness. This development highlights the rapid progress being made in these therapies, creating a risk that policy decisions will be made without the informed participation of the deaf community.
The BDA is advocating for the principle 'nothing about us without us' to be applied consistently in UK policy-making related to gene editing. Lichy urges those responsible for policy-making to work with this ethos in mind, ensuring that the voices and perspectives of deaf people are central to national conversations about the future of gene-edited humans.
This call for inclusion raises broader ethical considerations surrounding emerging biotechnologies. As the UK grapples with the implications of gene editing, the BDA's intervention highlights the importance of equitable access to information and a meaningful say in shaping future policies for all segments of society – particularly those directly impacted by these advancements.
The UK's deaf community has been historically marginalised in discussions around healthcare. According to the NHS, people who are deaf or hard of hearing may face significant barriers in accessing health services and understanding their treatment options. The BDA warns that this exclusion from gene editing conversations risks exacerbating existing inequalities.